ArticleJournal of nanobiotechnology2022

CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.

Dan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.